BTIG analyst David Larsen maintained a Buy rating on CryoPort (CYRX – Research Report) yesterday and set a price target of $20.00. The company’s shares closed last Friday at $15.49.
According to TipRanks, Larsen is an analyst with an average return of -6.6% and a 34.68% success rate. Larsen covers the Healthcare sector, focusing on stocks such as LifeMD, Apollo Medical Holdings, and Health Catalyst.
CryoPort has an analyst consensus of Moderate Buy, with a price target consensus of $17.40.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $26.01 and a one-year low of $9.00. Currently, CryoPort has an average volume of 625.3K.
Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CYRX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CryoPort (CYRX) Company Description:
CryoPort, Inc. engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers. It offers personalized medicine, immunotherapies, cellular therapies, CAR T-cell therapies, stem cell therapies, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals, infectious substances, and other commodities that require continuous exposure to certain ranges of precision-controlled temperatures. The company was founded on May 25, 1990 and is headquartered in Irvine, CA.
Read More on CYRX:
- Cryoport announces strategic partnership with Nippon Express Holdings
- Cryoport’s CRYOPDP Expands U.S. Footprint with Acquisition of Bluebird Express
- Cryoport’s Cryopdp expands acquires Bluebird Express
- Cryoport price target lowered to $20 from $28 at BTIG
- Cryoport price target lowered to $18 from $25 at Roth MKM
